Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (DE:BRM)
XETRA:BRM
Bristol-Myers Squibb (BRM) Stock Price & Analysis
14 Followers
BRM Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€40.64 - €61.46
Previous Close€40.74
Volume112.00
Average Volume (3M)2.75K
Market Cap
€82.50B
Enterprise Value€125.77B
Total Cash (Recent Filing)$9.67B
Total Debt (Recent Filing)$55.68B
Price to Earnings (P/E)N/A
Beta0.05
Next Earnings
Jul 26, 2024EPS Estimate
€1.56Last Dividend Ex-Date
Apr 04, 2024Dividend Yield5.35%
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,027,100,096
10 Day Avg. Volume6,154
30 Day Avg. Volume2,748
Standard Deviation0.06
R-Squared0.07
Alpha0.00426
Financial Highlights & Ratios
Price to Book (P/B)-2.33
Price to Sales (P/S)6.96
Price to Cash Flow (P/CF)7.80
P/FCF Ratio7.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.78
Enterprise Value/Gross Profit3.67
Enterprise Value/Ebitda30.41
Forecast
1Y Price Target
€49.13Price Target Upside20.75% Upside
Rating ConsensusHold
Number of Analyst Covering17
Bristol-Myers Squibb News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRevenues were ahead of estimates, with significant contributions from mature products like Revlimid.
Research And DevelopmentThe company's cost savings effort will be reinvested into R&D and marketing to support growth potential from recent acquisitions.
Stock ValuationAnalyst maintains a Market Perform rating, indicating that the stock is fairly valued with stable cash flows from I/O and hematology businesses.
Bears Say
Financial PerformanceAnalyst cuts the target price to USD45 from USD50 due to lower earnings estimates and higher net debt, implying a limited upside hence the Hold rating.
Patent Cliffs And NegotiationsThe market is debating the timing of the earnings trough for Bristol-Myers Squibb due to patent cliffs and IRA negotiations, creating significant uncertainty in forecasting.
Product PerformanceUnderperformance from key growth products like Camzyos, Sotyktu, and Abecma highlight challenges in the growth portfolio.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.30% Insiders
24.13% Mutual Funds
26.74% Other Institutional Investors
48.82% Public Companies and
Individual Investors
BRM FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was €40.64 and its highest was €61.46 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Currently, no data Available
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Jul 26, 2024 which is in 83 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Apr 25, 2024. The company reported -€4.106 earnings per share for the quarter, beating the consensus estimate of -€4.118 by €0.011.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of €0.56 which represents an annual dividend yield of 5.35%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is €1.56.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,027,100,100 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of -€4.106 in its last earnings report, beating expectations of -€4.118. Following the earnings report the stock price went down -7.776%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Among the largest hedge funds holding Bristol-Myers Squibb’s share is PRIMECAP Management Co. It holds Bristol-Myers Squibb’s shares valued at 1B.
---
Bristol-Myers Squibb Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€49.13 (20.75% Upside)
€49.13 (20.75% Upside)
Blogger Sentiment
Bullish
DE:BRM Sentiment 92%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.15%
12-Months-Change
Fundamentals
Return on Equity
-25.45%
Trailing 12-Months
Asset Growth
5.04%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
---
BRM Company Deck
---
BRM Earnings Call
Q1 2024
0:00 / 0:00
---
BRM Revenue Breakdown
27.12% Eliquis
20.02% Opdivo
13.55% Revlimid
8.00% Orencia
31.31% Other
---
BRM Stock 12 Months Forecast
Average Price Target
€49.13
▲(20.75% Upside)
Technical Analysis
Best Analysts Covering BRM
1 Year
1 Year Success Rate
16/16 ratings generated profit
1 Year Average Return
+18.43%
reiterated a sell rating 26 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +18.43% per trade.
---